Ikena Oncology, Inc. (NASDAQ:IKNA) Shares Sold by BVF Inc. IL

BVF Inc. IL trimmed its holdings in Ikena Oncology, Inc. (NASDAQ:IKNA - Free Report) by 16.0% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 4,006,564 shares of the company's stock after selling 762,600 shares during the period. BVF Inc. IL owned 8.30% of Ikena Oncology worth $6,571,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. BNP Paribas Financial Markets acquired a new stake in Ikena Oncology in the 4th quarter valued at about $72,000. Northern Trust Corp increased its holdings in shares of Ikena Oncology by 19.7% in the fourth quarter. Northern Trust Corp now owns 57,565 shares of the company's stock valued at $94,000 after purchasing an additional 9,456 shares during the last quarter. JPMorgan Chase & Co. lifted its position in Ikena Oncology by 18,244.1% during the fourth quarter. JPMorgan Chase & Co. now owns 155,741 shares of the company's stock worth $255,000 after buying an additional 154,892 shares in the last quarter. Geode Capital Management LLC boosted its stake in Ikena Oncology by 5.6% during the third quarter. Geode Capital Management LLC now owns 271,026 shares of the company's stock worth $469,000 after buying an additional 14,319 shares during the last quarter. Finally, Peapod Lane Capital LLC purchased a new stake in Ikena Oncology in the 4th quarter valued at $833,000. 75.00% of the stock is owned by hedge funds and other institutional investors.

Ikena Oncology Stock Up 5.6 %

Shares of IKNA traded up $0.06 during midday trading on Friday, reaching $1.14. The company had a trading volume of 52,360 shares, compared to its average volume of 169,058. The firm has a 50 day simple moving average of $1.24 and a 200-day simple moving average of $1.47. The stock has a market cap of $55.01 million, a PE ratio of -0.93 and a beta of 0.47. Ikena Oncology, Inc. has a 1-year low of $0.97 and a 1-year high of $1.94.

Ikena Oncology (NASDAQ:IKNA - Get Free Report) last issued its earnings results on Monday, May 12th. The company reported ($0.18) EPS for the quarter, topping analysts' consensus estimates of ($0.21) by $0.03. As a group, sell-side analysts anticipate that Ikena Oncology, Inc. will post -0.91 earnings per share for the current fiscal year.

Ikena Oncology Company Profile

Ikena Oncology, Inc operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway.